Related references
Note: Only part of the references are listed.Physiological and Oncogenic Aurora-A Pathway
Toshiaki SAEKI et al.
International Journal of Biological Sciences (2012)
Role of Glutathione Transferases in the Mechanism of Brostallicin Activation
Silvia Pezzola et al.
BIOCHEMISTRY (2010)
NVP-BEZ235 as a New Therapeutic Option for Sarcomas
Maria C. Manara et al.
CLINICAL CANCER RESEARCH (2010)
Denosumab in patients with giant-cell tumour of bone: an open-label, phase 2 study
David Thomas et al.
LANCET ONCOLOGY (2010)
The Role of Interferons in the Treatment of Osteosarcoma
Jeremy Whelan et al.
PEDIATRIC BLOOD & CANCER (2010)
ABC transporters in cancer: more than just drug efflux pumps
Jamie I. Fletcher et al.
NATURE REVIEWS CANCER (2010)
Correlation Between Clinical Outcome and Growth Factor Pathway Expression in Osteogenic Sarcoma
Ayesha Abdeen et al.
CANCER (2009)
Addition of Muramyl Tripeptide to Chemotherapy for Patients With Newly Diagnosed Metastatic Osteosarcoma
Alexander J. Chou et al.
CANCER (2009)
The Insulin-like Growth Factor-1 Receptor-Targeting Antibody, CP-751,871, Suppresses Tumor-Derived VEGF and Synergizes with Rapamycin in Models of Childhood Sarcoma
Raushan T. Kurmasheva et al.
CANCER RESEARCH (2009)
Insulin Receptor Isoform A and Insulin-like Growth Factor II as Additional Treatment Targets in Human Osteosarcoma
Sofia Avnet et al.
CANCER RESEARCH (2009)
Functional genome screen for therapeutic targets of osteosarcoma
Umio Yamaguchi et al.
CANCER SCIENCE (2009)
The role of mTOR in the management of solid tumors: An overview
Alex S. Strimpakos et al.
CANCER TREATMENT REVIEWS (2009)
A Phase I Dose-Escalation Study of Danusertib (PHA-739358) Administered as a 24-Hour Infusion with and without Granulocyte Colony-Stimulating Factor in a 14-Day Cycle in Patients with Advanced Solid Tumors
Roger B. Cohen et al.
CLINICAL CANCER RESEARCH (2009)
Inhibition of Src Phosphorylation Alters Metastatic Potential of Osteosarcoma In vitro but not In vivo
Pooja Hingorani et al.
CLINICAL CANCER RESEARCH (2009)
Zoledronic Acid Inhibits Both the Osteolytic and Osteoblastic Components of Osteosarcoma Lesions in a Mouse Model
Agatha Labrinidis et al.
CLINICAL CANCER RESEARCH (2009)
Targeted Therapies in Bone Sarcomas
K. Scotlandi et al.
CURRENT CANCER DRUG TARGETS (2009)
Novel agents in development for pediatric sarcomas
Dennis P. M. Hughes
CURRENT OPINION IN ONCOLOGY (2009)
Phase 3 randomised study of canfosfamide (Telcyta (R), TLK286) versus pegylated liposomal doxorubicin or topotecan as third-line therapy in patients with platinum-refractory or -resistant ovarian cancer
I. Vergote et al.
EUROPEAN JOURNAL OF CANCER (2009)
Prognostic factors and outcomes for osteosarcoma: An international collaboration
Emilios E. Pakos et al.
EUROPEAN JOURNAL OF CANCER (2009)
Novel therapeutic agents for osteosarcoma
Kathleen O'Day et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2009)
Muramyl tripeptide (mifamurtide) for the treatment of osteosarcoma
Paul A. Meyers
EXPERT REVIEW OF ANTICANCER THERAPY (2009)
Mechanisms of Gene Amplification and Evidence of Coamplification in Drug-Resistant Human Osteosarcoma Cell Lines
Claudia M. Hattinger et al.
GENES CHROMOSOMES & CANCER (2009)
Phase I Pharmacokinetic and Pharmacodynamic Study of the Aurora Kinase Inhibitor Danusertib in Patients With Advanced or Metastatic Solid Tumors
Neeltje Steeghs et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Phase 1-2a Multicenter Dose-Ranging Study of Canfosfamide in Combination with Carboplatin and Paclitaxel as First-Line Therapy for Patients with Advanced Non-small Cell Lung Cancer
Lecia V. Sequist et al.
JOURNAL OF THORACIC ONCOLOGY (2009)
ABC Transporters as Potential Targets for Modulation of Drug Resistance
L. Gatti et al.
MINI-REVIEWS IN MEDICINAL CHEMISTRY (2009)
Sorafenib blocks tumour growth, angiogenesis and metastatic potential in preclinical models of osteosarcoma through a mechanism potentially involving the inhibition of ERK1/2, MCL-1 and ezrin pathways
Ymera Pignochino et al.
MOLECULAR CANCER (2009)
Clinical impact of the methotrexate resistance-associated genes C-MYC and dihydrofolate reductase (DHFR) in high-grade osteosarcoma
I. Scionti et al.
ANNALS OF ONCOLOGY (2008)
Autophagy: A novel mechanism of synergistic cytotoxicity between doxorubicin and roscovitine in a sarcoma model
Laura A. Lambert et al.
CANCER RESEARCH (2008)
Overcoming glutathione S-transferase P1-related cisplatin resistance in osteosarcoma
Michela Pasello et al.
CANCER RESEARCH (2008)
Specific tyrosine kinase inhibitors regulate human osteosarcoma cells in vitro
Patrick J. Messerschmitt et al.
CLINICAL ORTHOPAEDICS AND RELATED RESEARCH (2008)
Novel bone cancer drugs: investigational agents and control paradigms for primary bone sarcomas (Ewing's sarcoma and osteosareoma)
Pete Anderson et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2008)
Farnesyl diphosphate synthase is involved in the resistance to zoledronic acid of osteosarcoma cells
B. Ory et al.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2008)
Phase I trial of the novel mammalian target of rapamycin inhibitor deforolimus (AP23573; MK-8669) administered intravenously daily for 5 days every 2 weeks to patients with advanced malignancies
Monica M. Mita et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Osteosarcoma: The addition of muramyl tripeptide to chemotherapy improves overall survival - A report from the Children's Oncology Group
Paul A. Meyers et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Novel therapeutic strategy for osteosarcoma targeting osteoclast differentiation, bone-resorbing activity, and apoptosis pathway
Toru Akiyama et al.
MOLECULAR CANCER THERAPEUTICS (2008)
Initial testing of the VEGFR inhibitor AZD2171 by the pediatric preclinical testing program
John M. Maris et al.
PEDIATRIC BLOOD & CANCER (2008)
Initial testing of dasatinib by the Pediatric Preclinical Testing Program
E. Anders Kolb et al.
PEDIATRIC BLOOD & CANCER (2008)
Initial testing (stage 1) of the mTOR inhibitor rapamycin by the pediatric preclinical testing program
Peter J. Houghton et al.
PEDIATRIC BLOOD & CANCER (2008)
Zoledronic acid inhibits osteosarcoma growth in an orthotopic model
Crispin R. Dass et al.
MOLECULAR CANCER THERAPEUTICS (2007)
Cyclin-dependent kinase inhibitors sensitize tumor cells to nutlin-induced apoptosis: a potent drug combination
Chit Fang Cheok et al.
MOLECULAR CANCER RESEARCH (2007)
Phase I study of everolimus in pediatric patients with refractory solid tumors
Maryam Fouladi et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Prognostic value of P-glycoprotein in high-grade osteosarcoma - Reply
Cindy L. Schwartz et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Prognostic value of P-glycoprotein in high-grade osteosarcoma
Massimo Serra et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Potential for treatment of liposarcomas with the MDM2 antagonist Nutlin-3A
Christoph R. Muller et al.
INTERNATIONAL JOURNAL OF CANCER (2007)
Adjuvant and neoadjuvant combination chemotherapy for osteogenic sarcoma
Stefano Ferrari et al.
CURRENT OPINION IN ONCOLOGY (2007)
Growth inhibition and sensitization to cisplatin by zoledronic acid in osteosarcoma cells
Maria Serena Benassi et al.
CANCER LETTERS (2007)
Multiple drug resistance in osteogenic sarcoma: INT0133 from the Children's Oncology Group
Cindy L. Schwartz et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Dasatinib inhibits migration and invasion in diverse human sarcoma cell lines and induces apoptosis in bone sarcoma cells dependent on Src kinase for survival
Audrey C. Shor et al.
CANCER RESEARCH (2007)
Recent advances in the management of osteosarcoma and forthcoming therapeutic strategies
Frangois Lamoureux et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2007)
A phase I trial of the selective oral cyclin-dependent kinase inhibitor seliciclib (CYC202; R-Roscovitine), administered twice daily for 7 days every 21 days
C. Benson et al.
BRITISH JOURNAL OF CANCER (2007)
Inhibitory effect of curcumin on MDR1 gene expression in patient leukemic cells
Songyot Anuchapreeda et al.
ARCHIVES OF PHARMACAL RESEARCH (2006)
Combined depletion of cell cycle and transcriptional cyclin-dependent kinase activities induces apoptosis in cancer cells
Dongpo Cai et al.
CANCER RESEARCH (2006)
Follow-up study of long-term survivors of osteosarcoma in the prechemotherapy era
Robyn Gaffney et al.
HUMAN PATHOLOGY (2006)
Modulation of the function of the multidrug resistance-linked ATP-binding cassette transporter ABCG2 by the cancer chemopreventive agent curcumin
Wanida Chearwae et al.
MOLECULAR CANCER THERAPEUTICS (2006)
Chemotherapy resistance in osteosarcoma: current challenges and future directions
Alexander J. Chou et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2006)
Vascular endothelial growth factor expression in osteosarcoma
R. M. Charity et al.
CLINICAL ORTHOPAEDICS AND RELATED RESEARCH (2006)
CXCR4 and VEGF expression in the primary site and the metastatic site of human osteosarcoma: analysis within a group of patients, all of whom developed lung metastasis
Y Oda et al.
MODERN PATHOLOGY (2006)
Prognostic factors for osteosarcoma of the extremity treated with neoadjuvant chemotherapy - 15-year experience in 789 patients treated at a single institution
G Bacci et al.
CANCER (2006)
Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: Implications for therapy
C Tovar et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
Patterns of care and survival for patients aged under 40 years with bone sarcoma in Britain, 1980-1994
CA Stiller et al.
BRITISH JOURNAL OF CANCER (2006)
Roscovitine modulates DNA repair and senescence: Implications for combination chemotherapy
E Crescenzi et al.
CLINICAL CANCER RESEARCH (2005)
Interferon-α as the only adjuvant treatment in high-grade osteosarcoma:: Long term results of the Karolinska Hospital series
CR Müller et al.
ACTA ONCOLOGICA (2005)
Enhanced tumor regression and tissue repair when zoledronic acid is combined with ifosfamide in rat osteosarcoma
D Heymann et al.
BONE (2005)
Rapamycin inhibits ezrin-mediated metastatic behavior in a murine model of osteosarcoma
XL Wan et al.
CANCER RESEARCH (2005)
An expression signature classifies chemotherapy-resistant pediatric osteosarcoma
MB Mintz et al.
CANCER RESEARCH (2005)
Sarcomas and pharmacogenetics
P Biason et al.
PHARMACOGENOMICS (2005)
In vivo activation of the p53 pathway by small-molecule antagonists of MDM2
LT Vassilev et al.
SCIENCE (2004)
Analysis of dihydrofolate reductase and reduced folate carrier gene status in relation to methotrexate resistance in osteosarcoma cells
M Serra et al.
ANNALS OF ONCOLOGY (2004)
Biology and therapeutic advances for pediatric osteosarcoma
N Marina et al.
ONCOLOGIST (2004)
Cisplatin: mode of cytotoxic action and molecular basis of resistance
ZH Siddik
ONCOGENE (2003)
Small-molecule cyclin-dependent kinase modulators
AM Senderowicz
ONCOGENE (2003)
Genomic imbalances associated with methotrexate resistance in human osteosarcoma cell lines detected by comparative genomic hybridization-based techniques
CM Hattinger et al.
EUROPEAN JOURNAL OF CELL BIOLOGY (2003)
The association of P-glycoprotein with response to chemotherapy and clinical outcome in patients with osteosarcoma - A meta-analysis
EE Pakos et al.
CANCER (2003)
Value of P-glycoprotein and clinicopathologic factors as the basis for new treatment strategies in high-grade osteosarcoma of the extremities
M Serra et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Reduced folate carrier protein expression in osteosarcoma - Implications for the prediction of tumor chemosensitivity
I Ifergan et al.
CANCER (2003)
Share Paper
